Abstract 383P
Background
The body mass index (BMI) before therapy shows a variety of progression free survival (PFS), it was said in the BMI study <18.5 kg/m2, had a worse progression free survival, compared to BMI 18.5-24.9 kg/m and BMI >24.9 kg/m2. The neutrophil lymphocyte ratio before therapy showed a variety of progression free survival (PFS). It was said that NLR ≥ 3 patients study have a better progression free survival compared to those < 3, but these results are still contradictory. The aim of this study was to determine body mass index and neutrophil to lymphocyte ratio before therapy to predict 3-year progression free survival in patients with locally advanced nasopharyngeal carcinom.
Methods
Patients with locally advanced nasopharyngeal carcinoma (N=289) from 2015 until 2017 who underwent chemoradiation with and without adjuvant or neoadjuvant chemotherapy were enrolled. Body mass index before therapy was classified as <18.5 (underweight), 18.5-24.9 (normal), and >24.9 (overweight or obese) and the neutrophil to lymphocyte ratio before therapy was categorized as ≥3 and <3, using the Cox proportional hazard and Kaplan-Meier models.
Results
Body mass index 18.5-24.9 and 24.9 on Cox regression has a better 3-year PFS with adjusted hazard ratio (HR = 0.219; CI = 1.43-1.59; p = 0.025 and HR = 0.136 ; CI = 1.51-1.76; p = 0.025 ), BMI <18.5 indicates a lower 3-year PFS (HR=1.644; CI=1.28-1.56; P=0.001). While NLR ≥3 before therapy had a better 3-year PFS (HR=0.152; CI 1.37-1.53, p=0.001) than NLR <3 (HR=1.603; CI 1.52-1.69, p=0.013.
Conclusions
Patients with BMI<18.5 before therapy had a lower 3-year PFS, and BMI>24.9 had a 3-year higher PFS than the normal weight group and NLR ≥3 had a higher PFS than under 3. This study provides a good understanding better between BMI and PFS and NLR and PFS, but further research is needed to confirm the result in different populations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract